HARNESSING THE POWER OF IMMUNOTHERAPY

Immunotherapy could revolutionize cancer care by developing nontoxic, highly efficient and decisive cures that do not rely on chemotherapeutic agents. These treatments could be used in 60% of advanced cancer patients by 2025. Canada needs greater capacity to translate these therapies into patient care, and to help Canadian companies compete in a potential $40 billion market.

THE CENTER FOR COMMERCIALIZATION OF CANCER IMMUNOTHERAPY (C3I)

C3i will accelerate access to innovative cancer immunotherapies for patients. Operating out of the Hôpital Maisonneuve-Rosemont, C3i offers an integrated structure for the development, translation and commercialization of these ground breaking therapies.

A Canadian "one-stop-shop" solution for the development, translation, and commercialization of cancer immunotherapy.

Combines three interacting units providing:

- cutting edge biomarker and diagnostics tests
- good manufacturing practices standards
- rapid access to clinical trials and regulatory support

Will bring effective and affordable remedies more rapidly to Canadians and the world

MISSION Accelerate the discovery, commercialization and access to Cancer Immunotherapy.

VISION C3i will be Canada's catalyst for Cancer Immunotherapy Business Development.

C3i Center for Commercialisation of Cancer IMMUNOTHERAPY



5415 boulevard de l'Assomption
Montréal, QC Canada H1T 2M4

T 514-252-3400 ext. 5896
francois.bettez.cemtl@ssss.gouv.qc.ca

T 514-252-3400 ext. 5669
louisa.petropoulos.cemtl@ssss.gouv.qc.ca

ACCELERATING MARKET ACCESS OF **BREAKTHROUGH INNOVATIONS** TO FIGHT CANCER



C3i Center for Commercialisation of Cancer IMMUNOTHERAPY

A UNIQUE COMBINATION OF **ASSETS**

Support: Pharmas and Biotechs | Translate laboratory findings to the clinic | Outstanding Networking track record | Efficient Clinical trial research | A GMP facility for therapeutics production | Expertise in Regulatory processes | Expertise in immuno-therapy | Venture Capital Investment | A business oriented scientific-medical team

BIOMARKER UNIT

Bringing novel therapies to the clinic efficiently require diagnostic procedures for:

- Target identification
- Response prediction
- Immune monitoring
- Detection of minimal residual disease

Some tests will require specific development for a therapeutic approach

- The unit will design and validate novel companion tests for the market

Methods and quality assurance standards complying with requirements of regulatory agencies

Platforms equipped with state-of-the-art technologies

- Molecular Biology
  Next-generation sequencing, PCR, etc.
- Multi-Parameter
  Flow and Mass-Spectrometry
- Bioinformatic expert center
- Quality assurance personnel

GMP MANUFACTURING UNIT

State of the art, 37 000 sq ft
13 clean rooms
Capacity for 100 employees

Large Treatment Capacity

cGMP compliant
Fully Validated

Focus on T-cell manipulations
& transduction of immune cells

25 years of clinical
laboratory experience

Close connections with major
Canadian research centers and networks

Interactions with Health Canada, FDA and EMA (Canadian, US and European Regulatory bodies)

Privileged access to Canadian market
(clinical, regulatory, funding)

FACT : “more than minimally manipulated”
License Health Canada
Registered FDA, EMA

CLINICAL RESEARCH UNIT

Providing access to patients admissible to clinical trials in CI

The Unit will take advantage

- Host institution (~700000 population)
- Largest Oncology Network in Canada (20 centers)
- 7 millions population

Multicentric IRB process

Providing expertise in all phases of clinical trial development and implementation including regulatory process

Expertise in Reimbursement strategies

INNOVATION UNIT

- Identification of novel targets for CART
- Pre-clinical model to predict best combination of biologics for clinical trials
- Small molecule inhibitors of check point regulators
- Companion tests for CI
- Industrialisation of cellular therapies processes